Form 4: Cumberland Pharmaceuticals CEO A.J. Kazimi Reports Share Withholding for Tax Obligations and Option Grant

Cumberland Pharmaceuticals' CEO, A.J. Kazimi, reports the withholding of shares to cover tax obligations related to vesting shares and the acquisition of options.

Summary

• On March 23, 2024, A.J. Kazimi, CEO of Cumberland Pharmaceuticals, had 25,710 common stock shares withheld by the company at a price of $1.81 per share to cover tax obligations.
• Following this transaction, Kazimi directly owns 5,695,557 shares of Cumberland Pharmaceuticals.
• On March 25, 2024, Kazimi acquired options for 100,000 shares of Cumberland Pharmaceuticals stock with an exercise price of $1.88, expiring on March 25, 2029.
• After this transaction, Kazimi directly owns 368,000 options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions, which is neutral in sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The withholding of shares to cover tax obligations has a minor dilutive effect on existing shareholders.
• The option grant incentivizes the CEO to improve company performance, potentially benefiting shareholders.

Key Dates